ECSP066877A - Moduladores canabinoides de tetrahidro-indazol - Google Patents
Moduladores canabinoides de tetrahidro-indazolInfo
- Publication number
- ECSP066877A ECSP066877A EC2006006877A ECSP066877A ECSP066877A EC SP066877 A ECSP066877 A EC SP066877A EC 2006006877 A EC2006006877 A EC 2006006877A EC SP066877 A ECSP066877 A EC SP066877A EC SP066877 A ECSP066877 A EC SP066877A
- Authority
- EC
- Ecuador
- Prior art keywords
- tabrahidro
- indazol
- canabinoid modulators
- canabinoid
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención describe un compuesto modulador canabinoide de tetrahidro-indazol de fórmula I: y un método para uso en el tratamiento, alivio o prevención de un síndrome, trastorno o enfermedad mediado por el receptor canabinoide.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55589004P | 2004-03-24 | 2004-03-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP066877A true ECSP066877A (es) | 2006-11-24 |
Family
ID=34965110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2006006877A ECSP066877A (es) | 2004-03-24 | 2006-09-22 | Moduladores canabinoides de tetrahidro-indazol |
Country Status (22)
Country | Link |
---|---|
US (2) | US7452997B2 (es) |
EP (1) | EP1735286B1 (es) |
JP (1) | JP4825792B2 (es) |
CN (1) | CN1956964B (es) |
AR (1) | AR048341A1 (es) |
AT (1) | ATE540027T1 (es) |
AU (1) | AU2005228868B2 (es) |
BR (1) | BRPI0509207A (es) |
CA (1) | CA2561305C (es) |
CR (1) | CR8701A (es) |
DK (1) | DK1735286T3 (es) |
EA (1) | EA010887B1 (es) |
EC (1) | ECSP066877A (es) |
ES (1) | ES2378071T3 (es) |
IL (1) | IL178290A0 (es) |
MX (1) | MXPA06011017A (es) |
NO (1) | NO20064810L (es) |
PL (1) | PL1735286T3 (es) |
PT (1) | PT1735286E (es) |
TW (1) | TW200602324A (es) |
WO (1) | WO2005095353A1 (es) |
ZA (1) | ZA200608808B (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
WO2007038045A1 (en) * | 2005-09-23 | 2007-04-05 | Janssen Pharmaceutica, N.V. | Tetrahydro-indazolyl cannabinoid modulators |
CN101312725B (zh) * | 2005-09-23 | 2012-01-11 | 詹森药业有限公司 | 六氢-环辛四烯并吡唑***素调节剂 |
CN101312952B (zh) * | 2005-09-23 | 2012-12-26 | 詹森药业有限公司 | 四氢-环戊二烯并吡唑***素调节剂 |
US8378117B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
US8378096B2 (en) | 2005-09-23 | 2013-02-19 | Janssen Pharmaceutica N.V. | Hexahydro-cycloheptapyrazole cannabinoid modulators |
ES2375213T3 (es) * | 2005-09-23 | 2012-02-27 | Janssen Pharmaceutica Nv | Moduladores de cannabinoides de hexadhidro-cicloheptapirazol. |
WO2007095513A1 (en) * | 2006-02-14 | 2007-08-23 | Janssen Pharmaceutica, Nv | Tetrahydr0-2h-indaz0le derivatives for use as cannabinoid modulators |
US20070254911A1 (en) * | 2006-03-27 | 2007-11-01 | Mingde Xia | Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators |
US8012957B2 (en) | 2006-03-27 | 2011-09-06 | Janssen Pharmaceutica Nv | Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators |
WO2008054508A2 (en) * | 2006-04-13 | 2008-05-08 | Alza Corporation | Stable nanosized amorphous drug |
WO2008053341A2 (en) * | 2006-11-03 | 2008-05-08 | Glenmark Pharmaceuticals S.A. | Bridged bicyclic indazoles as cannabinoid receptor ligands |
EP1935420A1 (en) * | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
JP2010522182A (ja) * | 2007-03-21 | 2010-07-01 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Cb2受容体介在疼痛を処置する方法 |
CA2681381A1 (en) * | 2007-03-21 | 2008-09-25 | Janssen Pharmaceutica N.V. | Method for treating cb2 receptor mediated pain |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
US8338623B2 (en) * | 2007-07-09 | 2012-12-25 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US7943653B2 (en) * | 2007-08-13 | 2011-05-17 | Janssen Pharmaceutica N.V. | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators |
EP2240443B1 (en) * | 2008-01-08 | 2013-11-20 | Purdue Pharma LP | Proline analogs as ligands for cannabinoid receptors for the treatment of pain |
US20090215850A1 (en) * | 2008-02-27 | 2009-08-27 | Mingde Xia | Method for treating cb2 receptor mediated pain |
JP5425911B2 (ja) * | 2008-09-25 | 2014-02-26 | エフ.ホフマン−ラ ロシュ アーゲー | 脂質異常症及び関連疾患に対するfxrモジュレーターとしての2,3−置換インダゾール又は4,5,6,7−テトラヒドロ−インダゾール |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US10435375B2 (en) | 2015-05-05 | 2019-10-08 | Northwestern University | CXCR4 chemokine receptor modulators |
US9682940B2 (en) | 2015-08-25 | 2017-06-20 | Janssen Pharmaceutica Nv | Indazole derivatives useful as CB-1 inverse agonists |
CN105367498B (zh) * | 2015-11-11 | 2019-05-17 | 中国农业大学 | 吡唑并环-3-甲酰胺类似物及其制备和应用 |
CN106397218A (zh) * | 2016-09-04 | 2017-02-15 | 王际菊 | S‑α‑环己基苯甲胺 |
US20210253562A1 (en) * | 2018-07-03 | 2021-08-19 | Janssen Pharmaceutica Nv | Acylsufonamide compounds useful as ep3 receptor antagonists |
TWI768464B (zh) * | 2019-09-12 | 2022-06-21 | 大陸商四川海思科製藥有限公司 | 三環吡唑衍生物及其製備 |
WO2021047581A1 (zh) * | 2019-09-12 | 2021-03-18 | 四川海思科制药有限公司 | 一种六氢化苯并吡唑衍生物及其制备 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1052111B (it) * | 1972-02-29 | 1981-06-20 | Acraf | Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati |
US3895025A (en) * | 1973-03-29 | 1975-07-15 | Du Pont | 2-Benzimidazolethiol preparation |
EP0226624A1 (en) * | 1985-06-14 | 1987-07-01 | The Upjohn Company | Cyclopentapyrazole and tetrahydroindazole compounds |
US4861777A (en) | 1987-09-11 | 1989-08-29 | Mitsubishi Kasei Corporation | Pyrazole derivative and insecticidal and miticidal composition containing the derivative as active ingredient |
JPH06306053A (ja) * | 1993-01-29 | 1994-11-01 | Sagami Chem Res Center | 3−アゾールカルボン酸誘導体の製造方法及びその中間体 |
US5532237A (en) * | 1995-02-15 | 1996-07-02 | Merck Frosst Canada, Inc. | Indole derivatives with affinity for the cannabinoid receptor |
US6410533B1 (en) * | 2000-02-10 | 2002-06-25 | Genzyme Corporation | Antibacterial compounds |
US6653304B2 (en) * | 2000-02-11 | 2003-11-25 | Bristol-Myers Squibb Co. | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases |
JP2005510492A (ja) * | 2001-10-26 | 2005-04-21 | ユニバーシティ オブ コネチカット | 新規な種類の効力のあるカンナビミメティックリガンド |
WO2003087037A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
-
2005
- 2005-03-23 CN CN2005800160828A patent/CN1956964B/zh not_active Expired - Fee Related
- 2005-03-23 US US11/087,943 patent/US7452997B2/en not_active Expired - Fee Related
- 2005-03-23 JP JP2007505172A patent/JP4825792B2/ja not_active Expired - Fee Related
- 2005-03-23 BR BRPI0509207-8A patent/BRPI0509207A/pt not_active IP Right Cessation
- 2005-03-23 MX MXPA06011017A patent/MXPA06011017A/es unknown
- 2005-03-23 PL PL05732229T patent/PL1735286T3/pl unknown
- 2005-03-23 DK DK05732229.9T patent/DK1735286T3/da active
- 2005-03-23 CA CA2561305A patent/CA2561305C/en not_active Expired - Fee Related
- 2005-03-23 AT AT05732229T patent/ATE540027T1/de active
- 2005-03-23 WO PCT/US2005/009819 patent/WO2005095353A1/en active Application Filing
- 2005-03-23 PT PT05732229T patent/PT1735286E/pt unknown
- 2005-03-23 ES ES05732229T patent/ES2378071T3/es active Active
- 2005-03-23 TW TW094108873A patent/TW200602324A/zh unknown
- 2005-03-23 EA EA200601760A patent/EA010887B1/ru not_active IP Right Cessation
- 2005-03-23 EP EP05732229A patent/EP1735286B1/en active Active
- 2005-03-23 AU AU2005228868A patent/AU2005228868B2/en not_active Ceased
- 2005-03-28 AR ARP050101196A patent/AR048341A1/es not_active Application Discontinuation
-
2006
- 2006-09-22 EC EC2006006877A patent/ECSP066877A/es unknown
- 2006-09-25 IL IL178290A patent/IL178290A0/en unknown
- 2006-10-20 CR CR8701A patent/CR8701A/es unknown
- 2006-10-23 NO NO20064810A patent/NO20064810L/no not_active Application Discontinuation
- 2006-10-23 ZA ZA200608808A patent/ZA200608808B/en unknown
-
2008
- 2008-10-08 US US12/247,263 patent/US20090099143A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL1735286T3 (pl) | 2012-06-29 |
US20090099143A1 (en) | 2009-04-16 |
ATE540027T1 (de) | 2012-01-15 |
ES2378071T3 (es) | 2012-04-04 |
CN1956964A (zh) | 2007-05-02 |
US20050228034A1 (en) | 2005-10-13 |
BRPI0509207A (pt) | 2007-08-28 |
CA2561305A1 (en) | 2005-10-13 |
IL178290A0 (en) | 2006-12-31 |
EA010887B1 (ru) | 2008-12-30 |
NO20064810L (no) | 2006-12-22 |
MXPA06011017A (es) | 2007-03-21 |
DK1735286T3 (da) | 2012-04-02 |
TW200602324A (en) | 2006-01-16 |
AR048341A1 (es) | 2006-04-19 |
AU2005228868B2 (en) | 2012-02-09 |
CA2561305C (en) | 2013-07-30 |
CR8701A (es) | 2008-11-24 |
JP2007530577A (ja) | 2007-11-01 |
AU2005228868A1 (en) | 2005-10-13 |
WO2005095353A1 (en) | 2005-10-13 |
EP1735286A1 (en) | 2006-12-27 |
JP4825792B2 (ja) | 2011-11-30 |
US7452997B2 (en) | 2008-11-18 |
PT1735286E (pt) | 2012-03-05 |
EP1735286B1 (en) | 2012-01-04 |
ZA200608808B (en) | 2008-06-25 |
EA200601760A1 (ru) | 2007-02-27 |
CN1956964B (zh) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP066877A (es) | Moduladores canabinoides de tetrahidro-indazol | |
ECSP088315A (es) | Moduladores de hexahidro-ciclooctil pirazol cannabinoide | |
ECSP088316A (es) | Moduladores sustituidos de 3-amido-tetrahidro-indazolil cannabinoide | |
PA8637301A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa | |
SV2007002146A (es) | Difenilimidazopirimidina e imidazol aminas como inhibidores de beta-secretasa ref. am101727 | |
CR10433A (es) | Compuestos organicos y sus usos | |
GT200600046A (es) | Terapia de combinacion | |
DOP2005000025A (es) | Compuestos de heteroaril- y fenilsulfamoilo sustituidos | |
DOP2010000062A (es) | Derivados de ciclopropilamida | |
CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
GT200900065A (es) | Derivado de 2-piridincarboxamida que tiene efecto activador de gk | |
ECSP088468A (es) | Moduladores de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido | |
CL2007002388A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas. | |
CL2007002380A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica. | |
WO2009023653A3 (en) | Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators | |
ECSP088314A (es) | Moduladores de cannabinoides hexahidro-cicloheptapirazol | |
WO2008115705A3 (en) | Hexahydro-cycloheptapyrazole cannabinoid modulators | |
WO2006116660A3 (en) | Methods of inhibiting a gpr23 | |
ATE479691T1 (de) | 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren | |
CR9479A (es) | Moduladores canabinoides de tetrahidrotiopirano pirazol | |
UY30972A1 (es) | Moduladores cannabinoides hexahidro-ciclooctilpirazol | |
UY30971A1 (es) | Moduladores cannabinoides hexahidro-cicloheptapirazol |